MediPal Holdings Corporation (MAHLY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MediPal Holdings Corporation (MAHLY) trades at $15.75 with AI Score 48/100 (Grade C). MediPal Holdings Corporation, based in Tokyo, specializes in the wholesale distribution of pharmaceuticals and healthcare products across Japan. Market cap: $3.22B, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for MAHLY: MAHLY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MAHLY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MAHLY: the 1 perspectives are evenly split.
How is this calculated? →MediPal Holdings Corporation (MAHLY) Healthcare & Pipeline Overview
MediPal Holdings Corporation is a prominent Japanese wholesaler in the healthcare sector, specializing in pharmaceuticals, medical equipment, and a broad range of healthcare-related products, distinguished by its extensive service offerings and a robust distribution network.
What Is the Investment Thesis for MAHLY?
MediPal Holdings Corporation presents a compelling investment thesis driven by its strong market position in Japan's healthcare distribution sector, characterized by a market cap of $3.22B and a P/E ratio of 12.8. The company benefits from a diverse revenue stream, including pharmaceuticals, medical equipment, and ancillary healthcare services, which collectively contribute to a gross margin of 6.5%. Ongoing investments in orphan drug development and the expansion of its PMS services are expected to enhance revenue growth in the coming years. The company's ability to adapt to changing healthcare needs, coupled with a stable dividend yield of 2.50%, positions it favorably for long-term growth. However, potential risks include regulatory changes and market competition, particularly from companies like Gedeon Richter PLC (RGEDF). Overall, MediPal's strategic initiatives and solid financial foundation provide a robust platform for sustained growth.
Based on FMP financials and quantitative analysis
MAHLY Key Highlights
- Market cap of $3.22B indicates strong market presence in healthcare distribution.
- P/E ratio of 12.8 reflects a competitive valuation relative to industry peers.
- Profit margin of 1.1% underscores operational efficiency, albeit with room for improvement.
- Gross margin of 6.5% is indicative of the company's pricing power in a competitive market.
- Dividend yield of 2.50% offers investors a steady income stream amid growth initiatives.
Who Are MAHLY's Competitors?
MAHLY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| RGEDF Gedeon Richter PLC | $39.76 | +0.30% | $7.27B | 53 |
| CWB State Street SPDR Bloomberg Convertible Securities ETF | $105.34 | +0.92% | $4.62B | 47 |
| TDV ProShares - S&P Technology Dividend Aristocrats ETF | $100.89 | +1.33% | $293.21M | 47 |
| DAUG FT Vest U.S. Equity Deep Buffer ETF - August | $46.97 | +0.26% | $363.40M | 47 |
| KSTR KraneShares SSE STAR Market 50 Index ETF | $28.75 | +2.00% | $67.07M | 47 |
| FEDDX Fidelity Emerging Markets Discovery Fd | $22.90 | +0.62% | $1.51B | 47 |
| PEQSX Putnam Large Cap Value Fund | $43.95 | +1.31% | $51.40B | 47 |
| RWMBX American Funds Washington Mutual R2 | $65.59 | +0.74% | $147.31B | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MAHLY's Key Strengths?
- Diverse product portfolio encompassing pharmaceuticals, medical supplies, and healthcare services.
- Strong market presence in Japan with a well-established distribution network.
- Expertise in post-marketing surveillance and orphan drug development.
What Are MAHLY's Weaknesses?
- Low profit margin of 1.1%, indicating potential operational inefficiencies.
- Dependence on the Japanese market may limit growth opportunities abroad.
- Limited brand recognition outside Japan compared to global competitors.
What Could Drive MAHLY Stock Higher?
- Expansion into new therapeutic areas with a focus on orphan drugs expected to drive revenue growth.
- Continuous enhancement of post-marketing surveillance services to meet increasing regulatory demands.
- Strategic partnerships with healthcare providers to enhance service offerings and market reach.
What Are the Key Risks for MAHLY?
- Regulatory changes impacting the pharmaceutical distribution landscape.
- Intense competition from both domestic and international players in the healthcare sector.
- Economic downturns affecting healthcare spending and product demand.
What Are the Growth Opportunities for MAHLY?
- Expansion into Orphan Drugs: MediPal's investment in the development of orphan drugs represents a significant growth opportunity, targeting a market projected to reach $200 billion globally by 2025. With Japan's increasing focus on rare diseases, MediPal's strategic initiatives in this area could enhance its revenue streams and market presence over the next five years.
- Diversification of Product Offerings: The company aims to expand its product portfolio beyond pharmaceuticals to include more medical equipment and diagnostic tools. This diversification is expected to tap into a growing market, estimated at $50 billion in Japan by 2027, driven by technological advancements and increased healthcare spending.
- Enhancement of Post-Marketing Surveillance Services: MediPal's PMS services are critical for pharmaceutical manufacturers. As regulatory requirements become more stringent, the demand for these services is expected to grow, providing MediPal with a competitive edge and potential revenue growth in the next few years.
- Digital Transformation and Telehealth Solutions: The rise of telehealth presents an opportunity for MediPal to integrate digital solutions into its service offerings. By developing platforms for remote education and health insurance claims review, the company can enhance customer engagement and streamline operations, positioning itself for future growth.
- Strategic Partnerships and Collaborations: MediPal's ability to form strategic alliances with healthcare providers and manufacturers can drive growth. Collaborations in research and development, particularly in innovative healthcare solutions, could lead to new revenue streams and market expansion opportunities.
What Opportunities Does MAHLY Have?
- Growing demand for healthcare products driven by an aging population.
- Expansion into new therapeutic areas and product lines.
- Potential for digital transformation and telehealth integration.
What Threats Does MAHLY Face?
- Regulatory changes impacting the pharmaceutical distribution landscape.
- Intense competition from both domestic and international players.
- Economic downturns affecting healthcare spending and product demand.
What Are MAHLY's Competitive Advantages?
- Established distribution network across Japan enhances operational efficiency.
- Diverse product offerings reduce reliance on any single revenue stream.
- Strong relationships with healthcare providers and manufacturers foster loyalty.
- Investment in innovative services positions the company ahead of competitors.
- Long-standing market presence since 1898 builds brand trust and recognition.
What Does MAHLY Do?
Founded in 1898, MediPal Holdings Corporation has established itself as a leading wholesaler of prescription pharmaceuticals in Japan. The company, headquartered in Tokyo, has significantly expanded its operations beyond drug distribution to include a comprehensive array of healthcare-related products. These products encompass medical equipment, materials, clinical diagnostic reagents, and over-the-counter medications, catering to a diverse clientele that includes hospitals, clinics, and retail outlets. MediPal's commitment to innovation is evident in its post-marketing surveillance (PMS) services for pharmaceutical manufacturers and its investments in orphan drug development. The company also plays a vital role in the agricultural sector by providing raw materials for food processing, livestock feed additives, and veterinary medical equipment. Over the years, MediPal has diversified its offerings to include specialized services such as epidemiological and clinical studies, health insurance claims review, and remote educational programs. The company has also ventured into managing life and non-life insurance agencies, showcasing its versatility in the healthcare landscape. In 2009, MediPal rebranded from Mediceo Paltac Holdings Co., Ltd., reflecting its broader focus on healthcare solutions. With a workforce of approximately 13,075 employees, MediPal continues to strengthen its market position through strategic partnerships and a commitment to quality service.
What Products and Services Does MAHLY Offer?
- Wholesale distribution of prescription pharmaceuticals across Japan.
- Supply of medical equipment, materials, and clinical diagnostic reagents.
- Provision of post-marketing surveillance services for pharmaceutical manufacturers.
- Investment in the development of orphan drugs for rare diseases.
- Distribution of over-the-counter medications and cosmetics.
- Provision of raw materials for agriculture, fisheries, and livestock sectors.
How Does MAHLY Make Money?
- Revenue generated from wholesale distribution of pharmaceuticals and medical supplies.
- Income from specialized services such as PMS and clinical studies.
- Sales from ancillary products including cosmetics and veterinary supplies.
- Fees from health insurance claims review and medical coding services.
- Revenue from managing life and non-life insurance agencies.
What Industry Does MAHLY Operate In?
The healthcare distribution industry in Japan is characterized by a growing demand for pharmaceuticals and medical supplies, driven by an aging population and increasing healthcare expenditures. The market is projected to expand as healthcare providers seek efficient supply chain solutions and innovative products. MediPal Holdings Corporation is well-positioned within this landscape, competing with firms like Gedeon Richter PLC (RGEDF) and leveraging its extensive distribution network and diverse product offerings to capture market share. The ongoing trend towards integrated healthcare solutions presents opportunities for growth and collaboration among industry players.
Who Are MAHLY's Key Customers?
- Hospitals and clinics requiring a steady supply of pharmaceuticals.
- Dispensing pharmacies and retail outlets such as drugstores and supermarkets.
- Animal hospitals and livestock businesses needing veterinary products.
- Food manufacturers requiring raw materials and additives.
- Healthcare facilities utilizing specialized services and databases.
ROE 7%Key Financial Metrics
Return on equity for MediPal Holdings Corporation stands at 6.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.2%, showing how much profit it generates from its asset base. MAHLY trades at a trailing price-to-earnings ratio of 12.79, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.28 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 7.8%, the inverse of the P/E and a quick read on earnings relative to price.
MediPal Holdings Corporation (MAHLY) Valuation Context
Valued at $3.22B, MAHLY is classified as a mid-cap stock. Relative to its peer group, MAHLY's quantitative score of 48/100 is roughly in line with the peer average of 48/100.
Company Profile
MediPal Holdings Corporation operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Tokyo, JP. The company is led by CEO Shuichi Watanabe. MAHLY has traded publicly since 2009.
F-Score 5/9Financial Health
MediPal Holdings Corporation's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.96 places it in the grey zone, a middle ground that warrants monitoring.
FY2026 estForward Outlook
Wall Street analysts project MediPal Holdings Corporation revenue of about $3.80T for fiscal 2026, with EPS near $0.00. The estimate reflects 5 contributing analysts.
MAHLY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Diverse product portfolio encompassing pharmaceuticals, medical supplies, and healthcare services.
- Strong market presence in Japan with a well-established distribution network.
- Expertise in post-marketing surveillance and orphan drug development.
- Upcoming: Expansion into new therapeutic areas with a focus on orphan drugs expected to drive revenue growth.
Bear Case
- Low profit margin of 1.1%, indicating potential operational inefficiencies.
- Dependence on the Japanese market may limit growth opportunities abroad.
- Limited brand recognition outside Japan compared to global competitors.
- Potential: Regulatory changes impacting the pharmaceutical distribution landscape.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
MAHLY Latest News
No recent news available for MAHLY.
MAHLY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MAHLY.
Price Targets
Wall Street price target analysis for MAHLY.
MAHLY MoonshotScore
What does this score mean?
The MoonshotScore rates MAHLY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Shuichi Watanabe
CEO
Shuichi Watanabe has a robust background in healthcare management, having led MediPal Holdings Corporation since its rebranding in 2009. With a degree in business administration, he has over 20 years of experience in the pharmaceutical and healthcare sectors, focusing on operational efficiency and strategic growth.
Track Record: Under Watanabe's leadership, MediPal has expanded its product offerings and enhanced its service capabilities, positioning the company for sustained growth in a competitive market. His strategic initiatives have led to increased revenue and a stronger market presence.
MediPal Holdings Corporation ADR Information Unsponsored
An American Depositary Receipt (ADR) represents shares in a foreign company, allowing US investors to trade shares of non-US companies. MediPal Holdings Corporation's ADR, MAHLY, facilitates investment in the company's shares without the complexities of foreign stock exchanges.
- Home Market Ticker: Tokyo, JP
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: MAHL
MAHLY OTC Market Information
The OTC Other tier represents stocks traded on the over-the-counter market that do not meet the listing requirements of major exchanges like NYSE or NASDAQ. This tier often has lower liquidity and transparency compared to listed stocks, which can affect trading conditions.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lower liquidity compared to stocks listed on major exchanges can lead to price volatility.
- Limited regulatory oversight may result in less transparency regarding financial performance.
- Potential for wider bid-ask spreads, affecting the cost of buying and selling shares.
- Review the company's financial statements and earnings reports.
- Assess the competitive landscape and market position.
- Evaluate the management team's experience and track record.
- Monitor regulatory changes affecting the healthcare distribution sector.
- Consider currency risk associated with ADR investments.
- Established history since 1898, indicating stability and experience.
- Diverse product offerings and services enhancing market credibility.
- Strong relationships with healthcare providers and manufacturers.
What Investors Ask About MediPal Holdings Corporation (MAHLY) — Healthcare
What does MediPal Holdings Corporation do?
MediPal Holdings Corporation is a leading wholesaler of prescription pharmaceuticals in Japan, providing a wide range of healthcare-related products including medical equipment, clinical diagnostic reagents, and over-the-counter medications. The company also offers specialized services such as post-marketing surveillance for pharmaceutical manufacturers and invests in orphan drug development. Its diverse client base includes hospitals, clinics, and retail outlets, showcasing its comprehensive role in the healthcare distribution sector.
What do analysts say about MAHLY stock?
Analysts generally view MediPal Holdings Corporation as a stable player in the healthcare distribution sector, with a focus on its diverse revenue streams and ongoing investments in orphan drugs. Key valuation metrics such as a P/E ratio of 12.8 suggest a competitive position within the industry. Growth considerations include the company's ability to adapt to regulatory changes and market demands, which could influence its future performance.
What are the main risks for MAHLY?
MediPal Holdings Corporation faces several risks, including potential regulatory changes that could impact its operations in the pharmaceutical distribution landscape. Additionally, intense competition from both domestic and international players poses a threat to market share. Economic downturns may also affect healthcare spending, potentially leading to decreased demand for MediPal's products and services. Investors should carefully consider these factors when evaluating the company's risk profile.
What are the key factors to evaluate for MAHLY?
MediPal Holdings Corporation (MAHLY) holds an AI score of 48/100 (low). P/E: 12.8x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does MAHLY data refresh on this page?
MAHLY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MAHLY's recent stock price performance?
MediPal Holdings Corporation (MAHLY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio encompassing pharmaceuticals, medical supplies, and healthcare services. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MAHLY overvalued or undervalued right now?
MediPal Holdings Corporation (MAHLY) trades at 12.8x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying MAHLY?
Before investing in MediPal Holdings Corporation (MAHLY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.